Inventor profile of:

James Veltmeyer

City:

Oceanside, California

Country:

United States

Published Applications:

43

Last publication date:

2024-11-07

Top Assignees for applications by James Veltmeyer

The entities that hold a legal rights for patent applications filed by inventor Veltmeyer James:

Recent patent applications by Veltmeyer James

James Veltmeyer from Oceanside, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2024-11-07
US20240366677A1
Human necessities

Aneurysm Treatment by Exosomes

#2 | 2024-09-19
US20240307446A1
Human necessities

Generation and Utility of B Cell Subsets for Treatment of Chronic Obstructive Pulmonary Disease

#3 | 2024-08-15
US20240269148A1
Human necessities

Enhancement of Anti-Angiogenic Cancer Immunotherapy by Abortogenic Agents

#4 | 2024-07-18
US20240241119A1
Physics

PREDICTION OF STEM CELL THERAPY RESPONSIVENESS BY QUANTIFICATION OF PRE-EXISTING B REGULATORY CELLS

#5 | 2024-07-11
US20240226172A9
Human necessities

MESENCHYMAL STEM CELL THERAPY OF EPILEPSY AND SEIZURE DISORDERS

#6 | 2024-07-04
US20240216472A1
Human necessities

ENHANCED EFFICACY OF TOLEROGENIC VACCINATION

#7 | 2024-05-16
US20240156862A1
Human necessities

TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH MYELOID DERIVED SUPPRESSOR CELLS

#8 | 2024-04-25
US20240131076A1
Human necessities

MESENCHYMAL STEM CELL THERAPY OF EPILEPSY AND SEIZURE DISORDERS

#9 | 2024-03-21
US20240091269A1
Human necessities

TREATMENT OF BIPOLAR DISORDER USING MESENCHYMAL STEM CELLS AND MODIFICATION OF MESENCHYMAL STEM CELLS

#10 | 2024-03-14
US20240082356A1
Human necessities

TREATMENT OF COPD BY STIMULATION OF STEM CELL MOBILIZATION

#11 | 2024-03-07
US20240076679A1
Chemistry; metallurgy

GENE SILENCING THERAPY OF ACUTE RESPIRATORY DISORDER

#12 | 2024-02-15
US20240050485A1
Human necessities

TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY MESENCHYMAL STEM CELL APOPTOTIC BODIES AND COMPOSITIONS THEREOF

#13 | 2024-02-01
US20240034996A1
Chemistry; metallurgy

GENE MODIFIED IPSC DERIVED CELLULAR COMPOSITIONS FOR REGENERATION AND IMMUNE MODULATION

#14 | 2023-11-16
US20230364148A1
Human necessities

INHIBITION AND REVERSION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) BY ENDOTHELIAL CELL REGENERATION

#15 | 2023-06-22
US20230192901A1
Chemistry; metallurgy

INDUCTION OF CONCURRENT PULMONARY IMMUNE MODULATION AND REGENERATION BY PROTEIN MEDIATED CONJUGATION OF IMMUNE REGULATORY CELLS WITH ENDOGENOUS PROGENITOR CELLS

#16 | 2023-04-06
US20230107484A1
Human necessities

REDUCTION OF NEUTROPHIL EXTRACELLULAR TRAP FORMATION BY MESENCHYMAL STEM CELLS AND THEIR EXOSOMES

#17 | 2023-03-23
US20230090980A1
Human necessities

Stimulation of mesenchymal stem cell therapeutic activities by T regulatory cells

#18 | 2023-03-16
US20230085607A1
Human necessities

IVERMECTIN COMPOSITIONS FOR TREATMENT OF COVID-19

#19 | 2023-02-23
US20230057957A1
Human necessities

UMBILICAL CORD MESENCHYMAL STEM CELLS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND LUNG DEGENERATION

#20 | 2023-02-23
US20230057356A1
Human necessities

ENHANCEMENT OF UMBILICAL CORD MESENCHYMAL STEM CELL THERAPEUTIC ACTIVITY BY STIMULATORS OF T REGULATORY CELLS AND/OR CELLS EXPRESSING CD73

#21 | 2023-02-16
US20230047535A1
Human necessities

INDUCTION OF NEUROGENESIS USING UMBILICAL CORD DERIVED MESENCHYMAL STEM CELLS AND DERIVATIVES THEREOF

#22 | 2023-01-12
US20230010501A1
Human necessities

TREATMENT OF PARKINSON'S DISEASE BY IMMUNE MODULATION AND REGENERATIVE MEANS

#23 | 2022-12-22
US20220403330A1
Chemistry; metallurgy

COMPOSITIONS CAPABLE OF STIMULATING IMMUNITY TOWARDS TUMOR BLOOD VESSELS

#24 | 2022-12-15
US20220395540A1
Human necessities

TREATMENT OF COVID-19 LUNG INJURY USING UMBILICAL CORD PLASMA BASED COMPOSITIONS

#25 | 2022-11-24
US20220370561A1
Human necessities

LITHIUM AS A MONOTHERAPY AND/OR STEM CELL ADJUVANT THERAPY FOR PULMONARY FIBROSIS

#26 | 2022-11-24
US20220370499A1
Human necessities

IMMUNOTHERAPIES FOR TARGETING OF TUMOR VASCULATURE

#27 | 2022-10-13
US20220323547A1
Human necessities

Amelioration and Treatment of Opioid Addiction

#28 | 2022-09-29
US20220306994A1
Chemistry; metallurgy

CHIMERIC CELLS COMPRISING DENDRITIC CELLS AND ENDOTHELIAL CELLS RESEMBLING TUMOR ENDOTHELIUM

#29 | 2022-09-22
US20220298491A1
Chemistry; metallurgy

PLURIPOTENT STEM CELL DERIVED DENDRITIC CELLS AND ENGINEERED DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY

#30 | 2022-09-08
US20220280574A1
Human necessities

THERAPEUTIC MONOCYTES FOR PREVENTION OF SUICIDAL IDEATION

#31 | 2022-08-25
US20220267730A1
Chemistry; metallurgy

EX VIVO GENERATION OF IMMUNOCYTES RECOGNIZING BROTHER OF THE REGULATOR OF IMPRINTED SITES (BORIS) EXPRESSING CANCER STEM CELLS

#32 | 2022-08-11
US20220249551A1
Human necessities

STIMULATION OF NATURAL KILL CELL MEMORY BY ADMINISTRATION OF DENDRITIC CELLS

#33 | 2022-07-28
US20220235325A1
Chemistry; metallurgy

STIMULATION OF DENDRITIC CELL ACTIVITY BY HOMOTAURINE AND ANALOGUES THEREOF

#34 | 2022-06-23
US20220193127A1
Human necessities

IMMUNOTHERAPY FOR OPIOID ADDICTION

#35 | 2022-06-09
US20220175701A1
Human necessities

TREATMENT OF MAJOR DEPRESSIVE DISORDER AND SUICIDAL IDEATIONS THROUGH STIMULATION OF HIPPOCAMPAL NEUROGENESIS UTILIZING PLANT-BASED APPROACHES

#36 | 2022-05-12
US20220143123A1
Human necessities

Prevention of Pathological Coagulation in COVID-19 and other Inflammatory Conditions

#37 | 2022-03-31
US20220096542A1
Human necessities

AUGMENTATION OF NATURAL KILLER CELL ACTIVITY AND INDUCTION OF CYTOTOXIC IMMUNITY USING LEUKOCYTE LYSATE ACTIVATED ALLOGENEIC DENDRITIC CELLS: STEMVACS

#38 | 2022-02-10
US20220040248A1
Human necessities

Prevention of neuroinflammation associated memory loss using nutraceutical compositions

#39 | 2022-02-03
US20220031793A1
Human necessities

Neuroprotection and neuroregeneration by pterostilbene and compositions thereof

#40 | 2022-01-27
US20220023237A1
Human necessities

ADDITIVE AND/OR SYNERGISTIC COMBINATIONS OF METFORMIN WITH NUTRACEUTICALS FOR THE PREVENTION, INHIBITION AND TREATMENT OF SARS-COV-2 AND ASSOCIATED COVID-19

#41 | 2022-01-25
US16901028
Human necessities

Nutraceuticals for suppressing indolamine 2,3 deoxygenase

#42 | 2021-12-23
US20210393681A1
Human necessities

Treatment of SARS-CoV-2 with Dendritic Cells for Innate and/or Adaptive Immunity

#43 | 2021-12-16
US20210386815A1
Human necessities

Nutraceuticals for Reducing Myeloid Suppressor Cells

InventorID:

5267727 ⎘